162 related articles for article (PubMed ID: 28972249)
1. Comparative study of two complementary proliferation markers in 200 breast carcinomas: Ki67 and mitotic index.
El Amine O; Ouni R; Adouni O; Goucha A; Ben Hassouna J; Rahal K; El May A; Gamoudi A
Tunis Med; 2016 Oct; 94(10):587-593. PubMed ID: 28972249
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of two complementary proliferation markers in 200 breast carcinomas: Ki67 and mitotic index.
El Amine O; Ouni R; Adouni O; Goucha A; Ben Hassouna J; Rahal K; El May A; Gamoudi A
Tunis Med; 2016 Oct; 94(8-9):587-593. PubMed ID: 28685793
[TBL] [Abstract][Full Text] [Related]
3. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index.
Jalava P; Kuopio T; Juntti-Patinen L; Kotkansalo T; Kronqvist P; Collan Y
Histopathology; 2006 May; 48(6):674-82. PubMed ID: 16681683
[TBL] [Abstract][Full Text] [Related]
4. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
[TBL] [Abstract][Full Text] [Related]
5. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
Hida AI; Bando K; Sugita A; Maeda T; Ueda N; Matsukage S; Nakanishi M; Kito K; Miyazaki T; Ohtsuki Y; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Aogi K; Moriya T
J Clin Pathol; 2015 May; 68(5):356-61. PubMed ID: 25673730
[TBL] [Abstract][Full Text] [Related]
6. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma.
Vartanian RK; Weidner N
Am J Pathol; 1994 Jun; 144(6):1188-94. PubMed ID: 7515558
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
Bertucci F; Finetti P; Roche H; Le Doussal JM; Marisa L; Martin AL; Lacroix-Triki M; Blanc-Fournier C; Jacquemier J; Peyro-Saint-Paul H; Viens P; Sotiriou C; Birnbaum D; Penault-Llorca F
Ann Oncol; 2013 Mar; 24(3):625-32. PubMed ID: 23117074
[TBL] [Abstract][Full Text] [Related]
8. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1.
Keshgegian AA; Cnaan A
Am J Clin Pathol; 1995 Jul; 104(1):42-9. PubMed ID: 7611179
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
[TBL] [Abstract][Full Text] [Related]
10. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
[TBL] [Abstract][Full Text] [Related]
11. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study.
Varga Z; Cassoly E; Li Q; Oehlschlegel C; Tapia C; Lehr HA; Klingbiel D; Thürlimann B; Ruhstaller T
PLoS One; 2015; 10(4):e0123435. PubMed ID: 25885288
[TBL] [Abstract][Full Text] [Related]
12. Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas.
Ahmed ST; Ahmed AM; Musa DH; Sulayvani FK; Al-Khyatt M; Pity IS
Asian Pac J Cancer Prev; 2018 Apr; 19(4):955-959. PubMed ID: 29693354
[TBL] [Abstract][Full Text] [Related]
13. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors.
González-Vela MC; Garijo MF; Fernández F; Val-Bernal JF
Histol Histopathol; 2001 Apr; 16(2):399-406. PubMed ID: 11332695
[TBL] [Abstract][Full Text] [Related]
14. [The relationship of the expression of proliferetron--related antigens Ki67 and PCNA in the cells of ductal breast cancer with the differentiation grade].
Surowiak P; Pudełko M; Maciejczyk A; Dziegiel P; Wojnar A; Zabel M
Ginekol Pol; 2005 Jan; 76(1):9-14. PubMed ID: 15844560
[TBL] [Abstract][Full Text] [Related]
15. Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count.
Tawfik O; Kimler BF; Davis M; Stasik C; Lai SM; Mayo MS; Fan F; Donahue JK; Damjanov I; Thomas P; Connor C; Jewell WR; Smith H; Fabian CJ
Virchows Arch; 2007 Jun; 450(6):627-36. PubMed ID: 17458558
[TBL] [Abstract][Full Text] [Related]
16. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
Breast Cancer Res Treat; 2018 May; 169(1):33-42. PubMed ID: 29349710
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ.
Bosch DE; Kilgore MR; Schmidt RA; Swanson PE; Rendi MH; Chang OH
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):543-547. PubMed ID: 28885232
[TBL] [Abstract][Full Text] [Related]
18. Cell proliferation in breast tumours: analysis of histological parameters Ki67 and PCNA expression.
Sullivan RP; Mortimer G; Muircheartaigh IO
Ir J Med Sci; 1993 Sep; 162(9):343-7. PubMed ID: 7903289
[TBL] [Abstract][Full Text] [Related]
19. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
20. A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer.
Mu K; Li L; Yang Q; Yun H; Kharaziha P; Ye DW; Auer G; Lagercrantz SB; Zetterberg A
Ann Diagn Pathol; 2015 Aug; 19(4):243-8. PubMed ID: 26049669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
